Ozagrel sodium

Synonyms: 奥扎格雷钠; OKY-046 sodium
Ozagrel sodium (OKY-046 sodium) 是一种高选择性、口服有效的血栓素 A2 (TXA2) 合成酶抑制剂,IC50 值为 11 nM,通过抑制 TXA2 生成并增加前列环素 (PGI2) 产生而发挥抗血小板聚集、血管扩张和抗炎作用,可用于缺血性卒中、哮喘及血栓栓塞性疾病的研究。
产品编号: MS-S51878 纯度: 99.82% CAS No.: 189224-26-8 分子式: C13H11N2NaO2 分子量: 250.23
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Ozagrel sodium (OKY-046 sodium) 是一种高选择性、口服有效的血栓素 A2 (TXA2) 合成酶抑制剂,IC50 值为 11 nM,通过抑制 TXA2 生成并增加前列环素 (PGI2) 产生而发挥抗血小板聚集、血管扩张和抗炎作用,可用于缺血性卒中、哮喘及血栓栓塞性疾病的研究。

生物实验数据

生物活性 Ozagrel sodium (OKY-046 sodium) is a highly selective, orally effective thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM that exerts antiplatelet, vasodilatory, and anti-inflammatory effects by inhibiting TXA2 production and increasing prostacyclin (PGI2) generation, and can be used for research on ischemic stroke, asthma, and thromboembolic diseases.
IC50 & Target

TXA2/TP

11 nM ()

TXB2

 

体外研究
(In Vitro)

Ozagrel sodium 能显著抑制由 Arachidonic acid (MS-A69140) 诱导的血小板聚集,其 IC50 为 53.12 μM。
Ozagrel sodium (100 μM) 对血浆中 TXB2 的抑制率为 99.6%,但对 PGH2 没有抑制作用。

体内研究
(In Vivo)

Ozagrel sodium (10-20 mg/kg, p.o., 每天一次共 6-21 天) 显著改善 L-Methionine (MS-Z11087) 和双侧颈总动脉闭塞 (BCCAo) 手术诱导的内皮功能障碍、氧化应激和神经炎症。
Ozagrel (80 mg/kg, i.v., 单次给药) sodium 能减轻 Oleic acid (OA) (MS-M89265) 诱导的豚鼠肺损伤,降低单核细胞趋化蛋白-1 和白细胞介素-8 mRNA 的表达。

Animal Model: BCCAo induced vascular dementia (VaD) model established in Wistar rats of both sex and weighing 200 g
Dosage: 10 and 20 mg/kg
Administration: Oral administration (p.o.), once daily for 21 days
Result: Improved the endothelial dysfunction caused by L-methionine-induced impairment.
Shortened the latency period of evasion, increased the duration of stay in target quadrants and reduced the length of swimming path.
Significantly reduced cerebral TBARS levels, increased cerebral GSH content, inhibited cerebral AChE activity, and decreased cerebral MPO activity and levels of TNF-α and IL-6.
Reduced leukocyte infiltration, neuronal degeneration and necrosis, increased pyramidal neuron density.
Animal Model: Improved the endothelial dysfunction caused by L-methionine-induced impairment.
Shortened the latency period of evasion, increased the duration of stay in target quadrants and reduced the length of swimming path.
Significantly reduced cerebral TBARS levels, increased cerebral GSH content, inhibited cerebral AChE activity, and decreased cerebral MPO activity and levels of TNF-α and IL-6.
Reduced leukocyte infiltration, neuronal degeneration and necrosis, increased pyramidal neuron density.
Dosage: 10 and 20 mg/kg
Administration: Oral administration (p.o.), once daily for 6 days
Result: Improved the endothelial dysfunction caused by L-methionine-induced impairment.
Shortened the latency period of evasion, increased the duration of stay in target quadrants and reduced the length of swimming path.
Significantly reduced cerebral TBARS levels, increased cerebral GSH content, inhibited cerebral AChE activity, and decreased cerebral MPO activity and levels of TNF-α and IL-6.
Reduced neutrophil infiltration, alleviated neuronal degeneration and nuclear pyknosis, and improved vascular congestion state.
Animal Model: OA-induced lung Injury model established in male Hartley guinea pigs (420-500 g)
Dosage: 80 mg/kg
Administration: Intravenous injection (i.v.), single dose, 3 h after OA injection
Result: Significantly reduced the levels of TXB2 in BALF and plasma.
Reduced the expression of MCP-1 and IL-8 mRNA and the infiltration of macrophages and neutrophils.
Significantly reduced the total protein concentration in BALF.
性状 固体
颜色 White to off-white

化学信息

分子量 250.23
分子式 C13H11N2NaO2
CAS No. 189224-26-8
别名 奥扎格雷钠; OKY-046 sodium

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 50 mg/mL (199.82 mM; 超声助溶)

DMSO 中的溶解度 : 6.25 mg/mL (24.98 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM3.9963 mL19.9816 mL39.9632 mL99.9081 mL
5 mM0.7993 mL3.9963 mL7.9926 mL19.9816 mL
10 mM0.3996 mL1.9982 mL3.9963 mL9.9908 mL
15 mM0.2664 mL1.3321 mL2.6642 mL6.6605 mL
20 mM0.1998 mL0.9991 mL1.9982 mL4.9954 mL
H2O25 mM0.1599 mL0.7993 mL1.5985 mL3.9963 mL
30 mM0.1332 mL0.6661 mL1.3321 mL3.3303 mL
40 mM0.0999 mL0.4995 mL0.9991 mL2.4977 mL
50 mM0.0799 mL0.3996 mL0.7993 mL1.9982 mL
60 mM0.0666 mL0.3330 mL0.6661 mL1.6651 mL
80 mM0.0500 mL0.2498 mL0.4995 mL1.2489 mL
100 mM0.0400 mL0.1998 mL0.3996 mL0.9991 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础